The Effect of Simvastatin on Uterine Leiomyoma Development and Growth in Infertile Women
Status:
Recruiting
Trial end date:
2021-09-14
Target enrollment:
Participant gender:
Summary
Uterine leiomyomas with an estimated incidence of 50%-80% are the most common tumors of
female reproductive system. Statins as a HMG-CoA reductase inhibitors inhibit the mevalonate
pathway of cholesterol synthesis, thus have been known as a group of drugs used for treatment
of hypercholesterolemia. Statins inhibit proliferation of several cell types including
vascular smooth muscle, hepatocytes and other cell types. Leiomyomas are benign uterine
tumors characterized by smooth muscle proliferation and excessive deposition of extracellular
matrix. In the present study we aim to evaluate the effect of simvastatin on uterine
leiomyoma development and growth.